BACKGROUND Adjuvant/neoadjuvant chemotherapy in breast cancer patients may be associated with amenorrhea and a marked reduction in ovarian reserve. OBJECTIVES To assess the use of letrozole with follicle-stimulating hormone (FSH) in gonadotropin-releasing hormone (GnRH) analogue protocols, based on reported attempts to avoid the estradiol (E2) increase during controlled ovarian hyperstimulati...

BACKGROUND Microdose flare-up GnRH agonist and GnRH antagonist have become more popular in the management of poor ovarian responders (POR) in recent years; however, the optimal protocol for POR patients undergoing in vitro fertilization has still been a challenge. METHODS In this observational study design, two hundred forty four poor ovarian responders were retrospectively evaluated for thei...

STUDY QUESTION Do differences in endometrial gene expression exist after ovarian stimulation with four different regimens of triggering final oocyte maturation and luteal phase support in the same patient? SUMMARY ANSWER Significant differences in the expression of genes involved in receptivity and early implantation were seen between the four protocols. WHAT IS KNOWN ALREADY GnRH agonist t...

Background/introduction In managing women with large uterine fibroids, GnRH agonists can be used to reduce fibroid volume and decrease vascularity to enhance treatment outcomes with MRgFUS. GnRH agonists have been shown to reduce fibroid volume by as much as 30-40%. The purpose of this study was to examine the responsiveness of fibroids to pre-treatment with a GnRH agonist in relation to their ...

The aim. Minimization of the frequency recurrence endometrial hyperplasia (EH) in women reproductive age with overweight (OW) depending on tactics treatment.
 Materials and methods. 90 OW were selected. They, turn, divided into three groups: group 1 – 30 who took a gonadotropin-releasing hormone agonist (GnRH agonist), namely at dose 3.75 mg intramuscularly once every 28 days; 2 used proge...

GnRH antagonists induce a rapid decrease in LH and FSH, preventing and interrupting LH surges. Their properties do not require a desensitization period, and this allows their use in the late follicular phase. GnRH antagonists could replace GnRH agonists in controlled ovarian stimulation without their side-effects and their long desensitization period. Two protocols for assisted reproduction tec...

BACKGROUND During IVF or ICSI cycles, ovarian hyperstimulation syndrome (OHSS) is a major problem. The aim of this prospective, multicentre, comparative study (using historical controls) was to assess the efficacy of a GnRH antagonist protocol in preventing OHSS in selected patients who had experienced OHSS or had been at risk of OHSS in their previous IVF/ICSI attempt. METHODS AND RESULTS Pa...

BACKGROUND The traditional hCG 'trigger' for initiating final oocyte maturation exacerbates ovarian hyperstimulation syndrome (OHSS) in patients with an excessive follicular response because of its sustained stimulatory effect on the corpora lutea. However, a GnRH agonist trigger can produce a short duration endogenous LH surge which is adequate to initiate oocyte maturation, but allows the cor...